Review Article| Volume 37, ISSUE 1, P1-9, February 2010

Prostate Cancer: To Screen or Not to Screen?

  • Alex Shteynshlyuger
    Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, Siteman Cancer Center, 4960 Children's Place, Campus Box 8242, St Louis, MO 63110, USA
    Search for articles by this author
  • Gerald L. Andriole
    Corresponding author.
    Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, Siteman Cancer Center, 4960 Children's Place, Campus Box 8242, St Louis, MO 63110, USA
    Search for articles by this author


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Urologic Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Barry M.J.
        Screening for prostate cancer—the controversy that refuses to die.
        N Engl J Med. 2009; 360: 1351-1354
        • Holmberg L.
        Prostate cancer screening: the need for problem-solving that puts men's interests first.
        Eur Urol. 2009; 56: 34-37
        • U.S. Preventive Services Task Force
        Screening for prostate cancer: U.S. preventive services task force recommendation statement.
        Ann Intern Med. 2008; 149: 185-191
        • Andriole G.L.
        • Crawford E.D.
        • Grubb 3rd, R.L.
        • et al.
        PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial.
        N Engl J Med. 2009; 360 (Erratum in: N Engl J Med 2009 Apr 23;360(17):1797): 1310-1319
        • Schröder F.H.
        • Hugosson J.
        • Roobol M.J.
        • et al.
        ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study.
        N Engl J Med. 2009; 360: 1320-1328
      1. Horner MJ, Ries LAG, Krapcho M, et al, editors. SEER Cancer statistics review, 1975–2006. Bethesda (MD): National Cancer Institute. Table 23.9: cancer of the prostate. Available at: Accessed October 15, 2009.

        • Hugosson J.
        • Aus G.
        • Becker C.
        • et al.
        Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden.
        BJU Int. 2000; 85: 1078-1084
        • Bill-Axelson A.
        • Holmberg L.
        • Filén F.
        • et al.
        Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.
        J Natl Cancer Inst. 2008; 100: 1144-1154
        • Lev E.L.
        • Eller L.S.
        • Gejerman G.
        • et al.
        Quality of life of men treated for localized prostate cancer: outcomes at 6 and 12 months.
        Support Care Cancer. 2009; 17: 509-517
        • Couper J.W.
        • Love A.W.
        • Dunai J.V.
        • et al.
        The psychological aftermath of prostate cancer treatment choices: a comparison of depression, anxiety and quality of life outcomes over the 12 months following diagnosis.
        Med J Aust. 2009; 190: S86-S89
        • Litwin M.S.
        • Hays R.D.
        • Fink A.
        • et al.
        Quality-of-life outcomes in men treated for localized prostate cancer.
        JAMA. 1995; 273: 129-135
        • Litwin M.S.
        • Gore J.L.
        • Kwan L.
        • et al.
        Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer.
        Cancer. 2007; 109: 2239-2247
        • Sanda M.G.
        • Dunn R.L.
        • Michalski J.
        • et al.
        Quality of life and satisfaction with outcome among prostate-cancer survivors.
        N Engl J Med. 2008; 358: 1250-1261
        • Johansson E.
        • Bill-Axelson A.
        • Holmberg L.
        • et al.
        Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.
        Eur Urol. 2009; 55: 422-430
        • Draisma G.
        • Etzioni R.
        • Tsodikov A.
        • et al.
        Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.
        J Natl Cancer Inst. 2009; 101: 374-383
        • Welch H.G.
        • Albertsen P.C.
        Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005.
        J Natl Cancer Inst. 2009; 101: 1325-1329
        • Okotie O.T.
        • Roehl K.A.
        • Han M.
        • et al.
        Characteristics of prostate cancer detected by digital rectal examination only.
        Urology. 2007; 70: 1117-1120
        • Gosselaar C.
        • Roobol M.J.
        • Roemeling S.
        • et al.
        The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.
        Eur Urol. 2008; 54: 581-588
        • Thompson I.M.
        • Ernst J.J.
        • Gangai M.P.
        • et al.
        Adenocarcinoma of the prostate: results of routine urological screening.
        J Urol. 1984; 132: 690-692
        • Philip J.
        • Hanchanale V.
        • Foster C.S.
        • et al.
        Importance of peripheral biopsies in maximizing the detection of early prostate cancer in repeat 12-core biopsy protocols.
        BJU Int. 2006; 98: 559-562
        • Pepe P.
        • Aragona F.
        Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation.
        Urology. 2007; 70: 1131-1135
        • Jones J.S.
        • Patel A.
        • Schoenfield L.
        • et al.
        Saturation technique does not improve cancer detection as an initial prostate biopsy strategy.
        J Urol. 2006; 175: 485-488
        • Thompson I.M.
        • Ankerst D.P.
        • Chi C.
        • et al.
        Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.
        JAMA. 2005; 294: 66-70
        • Thompson I.M.
        • Pauler D.K.
        • Goodman P.J.
        • et al.
        Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter.
        N Engl J Med. 2004; 350: 2239-2246
        • Raaijmakers R.
        • Kirkels W.J.
        • Roobol M.J.
        • et al.
        Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program.
        Urology. 2002; 60: 826-830
        • Djavan B.
        • Waldert M.
        • Zlotta A.
        • et al.
        Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study [review].
        J Urol. 2001; 166: 856-860
        • Haas G.P.
        • Delongchamps N.B.
        • Jones R.F.
        • et al.
        Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence.
        J Natl Cancer Inst. 2007; 99: 1484-1489
        • Seitz M.
        • Gratzke C.
        • Schlenker B.
        • et al.
        Contrast-enhanced transrectal ultrasound (CE-TRUS) with cadence-contrast pulse sequence (CPS) technology for the identification of prostate cancer.
        Urol Oncol. 2009; ([Epub ahead of print])
        • Shimizu T.
        • Nishie A.
        • Ro T.
        • et al.
        Prostate cancer detection: the value of performing an MRI before a biopsy.
        Acta Radiol. 2009; 50: 1080-1088
        • Boyle P.
        • Brawley O.W.
        Prostate cancer: current evidence weighs against population screening.
        CA Cancer J Clin. 2009; 59: 220-224
        • U.S. Census
        Bureau, statistical abstract of the United States: 2009.
        (128th edition). 2008 (Washington, DC; 2008. Table 103: expectation of life and expected deaths by race, sex, and age: 2005. Available at:) (Accessed October 10, 2009)
        • Nguyen P.L.
        • Chen M.H.
        • Renshaw A.A.
        • et al.
        Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: implications for screening recommendations.
        Int J Radiat Oncol Biol Phys. 2009; ([Epub ahead of print])
        • Shappley 3rd, W.V.
        • Kenfield S.A.
        • Kasperzyk J.L.
        • et al.
        Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort.
        J Clin Oncol. 2009; 27: 4980-4985